References
- 1. R. Duncan, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer6 (2006) 688–701; DOI: 10.1038/Nrc1958.
- 2. M. J. Vicent and R. Duncan, Polymer conjugates: nanosized medicines for treating cancer, Trends Biotechnol. 24 (2006) 39–47; DOI: 10.1016/j.tibtech.2005.11.006.
- 3. R. Haag and F. Kratz, Polymer the rapeutics: concepts and applications, Angew Chem. Int. Ed. Engl. 45 (2006) 1198–1215; DOI: 10.1002/anie.200502113.
- 4. A. A. Adjei, Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent, Clin. Cancer Res.10 (2004) 4276–4280; DOI: 10.1158/1078-0432.CCR-040010.
- 5. R. B. Zhao, N. Diop-Bove, M. Visentin and I. D. Goldman, Mechanisms of membrane transport of folates into cells and across epithelia, Ann. Rev. Nutr. 31 (2011) 177–201; DOI: 10.1146/annurev-nutr-072610-145133.
- 6. J. E. Nutt, A. R. Razak, K. O’Too le, F. Black, A. E. Quinn, A. H. Calvert, E. R. Plummer and J. Lunec, The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy, Br. J. Cancer102 (2010) 553–560; DOI: 10.1038/sj.bjc.6605501.
- 7. W. H. Schuette, A. Groschel, M. S ebastian, S. Andreas, T. Muller, F. Schneller, S. Guetz, C. Eschbach, S. Bohnet, M. I. Leschinger and M. Reck, A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer, Clin. Lung Cancer14 (2013) 215–223; DOI: 10.1016/j.cllc.2012.10.001.
- 8. O. Caffo, L. Fratino, R. Barbieri, A. Perin, T. Martini, T. Sava, R. Segati, E. Vaccher, F. Bernardo Bassan, A. Veccia, G. Pappagallo nad E. Galligioni, Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study, Urol Oncol. 31 (2013) 180–186; DOI: 10.1016/j.urolonc.2010.11.012.
- 9. A. A. Adjei, Pharmacology and mechanism of action of pemetrexed, Clin. Lung Cancer5 (2004) 51–55; DOI: 10.3816/CLC.2004.s.003.
- 10. R. Budzynska, D. Nevozhay, U. Kanska, M. Jagiello, A. Opolski, J. Wietrzyk and J. Boratynski, Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo, Oncol. Res. 16 (2007) 415–421.
- 11. D. Nevozhay, R. Budzynska, U. Kanska, M. Jagiello, M. S. Omar, J. Boratynski and A. Opolski, Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier, Anticancer Res. 26 (2006) 1135–1143.
- 12. A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, T. Tamura, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment, Bioorg. Med. Chem. 17 (2009) 4647–4656; DOI: 10.1016/j.bmc.2009.04.063.
- 13. T. M. Goszczynski, B. Filip-Psurska, K. Kempinska, J. Wietrzyk and J. Boratynski, Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy, Pharmacol. Res. Perspect. 2 (2014) 1–8; DOI: 10.1002/prp2.47.
- 14. M. Westphal, M. F. James, S. Kozek-Langenecker, R. Stocker, B. Guidet and H. Van Aken, Hydroxyethyl starches: different products-different effects, Anesthesiology111 (2009) 187–202; DOI: 10.1097/ALN.0b013e3181a7ec82.
- 15. T. Masuko, A. Minami, N. Iwasaki, T. Majima, S. Nishimura and Y. C. Lee, Carbohydrate analysis by a phenol-sulfuric acid method in microplate format, Anal. Biochem. 339 (2005) 69–72; DOI: 10.1016/j.ab.2004.12.001.